Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.

Thiele M, Rausch V, Fluhr G, Kjærgaard M, Piecha F, Mueller J, Straub BK, Lupșor-Platon M, De-Ledinghen V, Seitz HK, Detlefsen S, Madsen B, Krag A, Mueller S.

J Hepatol. 2018 May;68(5):1025-1032. doi: 10.1016/j.jhep.2017.12.029. Epub 2018 Jan 16.

PMID:
29343427
2.

Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.

Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, Ahn SH, Chon CY, Lee HW, Park Y, Han KH.

Liver Int. 2014 Jan;34(1):102-9. doi: 10.1111/liv.12282. Epub 2013 Sep 13.

PMID:
24028214
3.

Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.

Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Fan JG.

World J Gastroenterol. 2014 Apr 28;20(16):4702-11. doi: 10.3748/wjg.v20.i16.4702.

4.

Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.

Chan WK, Nik Mustapha NR, Mahadeva S.

J Gastroenterol Hepatol. 2014;29(7):1470-6. doi: 10.1111/jgh.12557.

PMID:
24548002
5.

Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.

Rout G, Kedia S, Nayak B, Yadav R, Das P, Acharya SK, Gunjan D, Singh V, Mahanta M, Gupta S, Aggarwal S, Shalimar.

J Clin Exp Hepatol. 2019 Jan-Feb;9(1):13-21. doi: 10.1016/j.jceh.2018.02.010. Epub 2018 Mar 14.

PMID:
30765934
6.

[Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].

Xu L, Li P, Lu W, Shi Q, Shi R, Zhang X, Liu Y, Wang Q, Fan J, Mi Y.

Zhonghua Gan Zang Bing Za Zhi. 2016 Feb;24(2):108-13. doi: 10.3760/cma.j.issn.1007-3418.2016.02.007. Chinese.

PMID:
26983477
7.

Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.

Lupșor-Platon M, Feier D, Stefănescu H, Tamas A, Botan E, Sparchez Z, Maniu A, Badea R.

J Gastrointestin Liver Dis. 2015 Mar;24(1):35-42. doi: 10.15403/jgld.2014.1121.mlp.

8.

Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.

de Lédinghen V, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, Chermak F, Choi PC, Foucher J, Chan CK, Merrouche W, Chim AM, Le Bail B, Wong VW.

J Gastroenterol Hepatol. 2016 Apr;31(4):848-55. doi: 10.1111/jgh.13219.

PMID:
26514665
9.

Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.

Garg H, Aggarwal S, Shalimar, Yadav R, Datta Gupta S, Agarwal L, Agarwal S.

Surg Obes Relat Dis. 2018 Jan;14(1):81-91. doi: 10.1016/j.soard.2017.09.005. Epub 2017 Sep 11.

PMID:
29126863
10.

Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B.

Liver Int. 2012 Jul;32(6):911-8. doi: 10.1111/j.1478-3231.2012.02820.x.

PMID:
22672642
11.

Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.

Andrade P, Rodrigues S, Rodrigues-Pinto E, Gaspar R, Lopes J, Lopes S, Macedo G.

GE Port J Gastroenterol. 2017 Jul;24(4):161-168. doi: 10.1159/000453364. Epub 2016 Dec 23.

12.

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.

Ahn JM, Paik YH, Min SY, Cho JY, Sohn W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Gut Liver. 2016 Mar;10(2):295-302. doi: 10.5009/gnl15155.

13.

Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.

Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Dal Bello B, Filice G, Filice C.

World J Gastroenterol. 2014 Jun 7;20(21):6626-31. doi: 10.3748/wjg.v20.i21.6626.

14.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28.

PMID:
28039099
15.

Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy.

Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, Fang YX, Li GL, Song YJ, Deng ZJ, Wu JM, Tang KF.

J Gastroenterol Hepatol. 2014 Jun;29(6):1149-58. doi: 10.1111/jgh.12519.

PMID:
24476011
16.

MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.

Runge JH, Smits LP, Verheij J, Depla A, Kuiken SD, Baak BC, Nederveen AJ, Beuers U, Stoker J.

Radiology. 2018 Feb;286(2):547-556. doi: 10.1148/radiol.2017162931. Epub 2017 Sep 15.

PMID:
28915103
17.

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

Wong VW, Petta S, Hiriart JB, Cammà C, Wong GL, Marra F, Vergniol J, Chan AW, Tuttolomondo A, Merrouche W, Chan HL, Le Bail B, Arena U, Craxì A, de Lédinghen V.

J Hepatol. 2017 Sep;67(3):577-584. doi: 10.1016/j.jhep.2017.05.005. Epub 2017 May 12.

PMID:
28506907
18.

Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Chan WK, Nik Mustapha NR, Wong GL, Wong VW, Mahadeva S.

United European Gastroenterol J. 2017 Feb;5(1):76-85. doi: 10.1177/2050640616646528. Epub 2016 Jun 23.

19.

Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases.

Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Takahashi S, Arihiro K, Chayama K.

Hepatol Res. 2013 Nov;43(11):1182-9. doi: 10.1111/hepr.12094. Epub 2013 Apr 2.

PMID:
23551911
20.

How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.

Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H.

Liver Int. 2014 Jul;34(6):e111-7. doi: 10.1111/liv.12305. Epub 2013 Sep 4.

PMID:
24034415

Supplemental Content

Support Center